Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Safety also depends on good clinical practice, so at Elon Health we: Rotate injection sites (left arm, right arm, glute) to reduce soreness or scar tissue
However, no clinical trials have evaluated this combination, and any multi-peptide or peptide-plus-GLP-1 protocol should be managed by a practitioner who can monitor labs, adjust doses, and watch for unexpected interactions
For those interested in hair health, peptides like GHK-Cu have actually shown hair-supportive properties
That study reported changes in hormone-sensitive lipase activity, acetyl-CoA carboxylase activity, diacylglycerol release, adipocyte size, and body-weight gain in the specific models used
Adjusting the dosage under medical supervision is recommended
| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) | The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials
